Vera Therapeutics (NASDAQ:VERA) vs. Pivotal Therapeutics (OTCMKTS:PVTTF) Financial Analysis

Pivotal Therapeutics (OTCMKTS:PVTTF) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Institutional & Insider Ownership

99.2% of Vera Therapeutics shares are owned by institutional investors. 21.7% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pivotal Therapeutics and Vera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pivotal Therapeutics	N/A	N/A	N/A
Vera Therapeutics	N/A	-47.57%	-36.94%

Analyst Ratings

This is a summary of current recommendations and price targets for Pivotal Therapeutics and Vera Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pivotal Therapeutics	0	0	0	0	N/A
Vera Therapeutics	0	1	6	1	3.00

Vera Therapeutics has a consensus target price of $43.86, suggesting a potential upside of 14.21%. Given Vera Therapeutics’ higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Pivotal Therapeutics.

Volatility and Risk

Pivotal Therapeutics has a beta of -0.52, suggesting that its share price is 152% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

Valuation & Earnings

This table compares Pivotal Therapeutics and Vera Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pivotal Therapeutics	N/A	N/A	N/A	N/A	N/A
Vera Therapeutics	N/A	N/A	-$95.99 million	($2.05)	-18.73

Summary

Vera Therapeutics beats Pivotal Therapeutics on 6 of the 8 factors compared between the two stocks.

About Pivotal Therapeutics

Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler’s health, child’s health, and pet’s health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.

About Vera Therapeutics

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.